These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. For Rahimi K Heart; 2023 Dec; 110(1):1-2. PubMed ID: 38101925 [No Abstract] [Full Text] [Related]
10. Clinical Effectiveness of the Cardiovascular Polypill in a Real-Life Setting in Patients with Cardiovascular Risk: The SORS Study. Castellano JM; Verdejo J; Ocampo S; Rios MM; Gómez-Álvarez E; Borrayo G; Ruiz E; Ibáñez B; Fuster V; Arch Med Res; 2019 Jan; 50(1):31-40. PubMed ID: 31101241 [TBL] [Abstract][Full Text] [Related]
11. Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States. Gaziano TA; Pandya A; Sy S; Jardim TV; Ogden JM; Rodgers A; Weinstein MC Am Heart J; 2019 Aug; 214():77-87. PubMed ID: 31174054 [TBL] [Abstract][Full Text] [Related]
12. Economic Burden Associated with the Treatment with a Cardiovascular Polypill in Secondary Prevention in Spain: Cost-Effectiveness Results of the NEPTUNO Study. Cordero A; Dalmau González-Gallarza R; Masana L; Fuster V; Castellano JM; Ruiz Olivar JE; Zsolt I; Sicras-Mainar A; González Juanatey JR Clinicoecon Outcomes Res; 2023; 15():559-571. PubMed ID: 37489131 [TBL] [Abstract][Full Text] [Related]
13. The changing landscape of drug clinical trials on cardiometabolic diseases in China, 2009-2021. Li C; Hao J; Zheng Y; Wang C; Yang J; Wang W; Zhang K; Shao C; Hui W; Wang J; Li W; Tang YD Diabetol Metab Syndr; 2023 Apr; 15(1):66. PubMed ID: 37005689 [TBL] [Abstract][Full Text] [Related]
14. The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context. McMurray JJV; Solomon SD; Docherty KF; Jhund PS Eur Heart J; 2021 Mar; 42(13):1199-1202. PubMed ID: 31898736 [No Abstract] [Full Text] [Related]
15. Polypill strategy at the heart of cardiovascular secondary prevention. Ibañez B; Castellano JM; Fuster V Heart; 2019 Jan; 105(1):9-10. PubMed ID: 30030331 [No Abstract] [Full Text] [Related]
16. A polypill strategy to improve adherence: results from the FOCUS project. Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393 [TBL] [Abstract][Full Text] [Related]
17. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality. Castellano JM; Sanz G; Fernandez Ortiz A; Garrido E; Bansilal S; Fuster V J Am Coll Cardiol; 2014 Aug; 64(6):613-21. PubMed ID: 25104532 [TBL] [Abstract][Full Text] [Related]
18. The polypill strategy in cardiovascular disease prevention: It's time for its implementation. Di Fusco SA; Aquilani S; Spinelli A; Alonzo A; Matteucci A; Castello L; Imperoli G; Colivicchi F Prog Cardiovasc Dis; 2023; 79():37-40. PubMed ID: 36931543 [TBL] [Abstract][Full Text] [Related]